These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9750238)

  • 1. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
    Mehrotra DV; Li X; Gilbert PB
    Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
    Gilbert PB; McKeague IW; Sun Y
    Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
    Desrosiers R
    J Int Assoc Physicians AIDS Care; 1998 Mar; 4(3):45-6. PubMed ID: 11365180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological considerations in the development of a human immunodeficiency virus vaccine.
    Nathanson N; Mathieson BJ
    J Infect Dis; 2000 Aug; 182(2):579-89. PubMed ID: 10915092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
    Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
    Flynn NM; Forthal DN; Harro CD; Judson FN; Mayer KH; Para MF;
    J Infect Dis; 2005 Mar; 191(5):654-65. PubMed ID: 15688278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chop-lump tests for vaccine trials.
    Follmann D; Fay MP; Proschan M
    Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
    Klein E; Ho RJ
    Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003.
    Suntharasamai P; Martin M; Vanichseni S; van Griensven F; Mock PA; Pitisuttithum P; Tappero JW; Sangkum U; Kitayaporn D; Gurwith M; Choopanya K;
    Addiction; 2009 Feb; 104(2):235-42. PubMed ID: 19149819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
    Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
    J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
    Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW
    J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.